Tuesday, 24 May 2022


South Korea’s SK bioscience expands manufacturing agreement for Novavax’s COVID-19 vaccine

27 December 2021 | News

SK bioscience secures long-term license to supply NVX-CoV2373 for the Korean market

image credit- shutterstock

image credit- shutterstock

Novavax, Inc. and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK Group, have announced the expansion of the companies' collaboration and license agreements for NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine.

The companies have agreed that SK bioscience will reserve significant additional manufacturing capacity to produce antigen, a key component of NVX-CoV2373, through 2022, with the possibility to extend the arrangement.

The agreement between the companies also builds on a previously announced advance purchase agreement (APA) between SK bioscience and the Korean government to supply 40 million doses of NVX-CoV2373 for the Republic of Korea.

SK bioscience may supply additional quantities of NVX-CoV2373 in the Korean market in 2022. Additionally, SK bioscience has acquired non-exclusive rights to sell doses of Novavax' vaccine to the governments of Thailand and Vietnam.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account